Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Crassula Pharmaceuticals is a global healthcare company headquartered in Florida, USA. It is positioned as a technology-driven CDMO/CMO for finished dosage formulations, rather than traditional SaaS software. Its business covers prescription drugs, OTC products, nutritional supplements, and cosmeceutical/beauty wellness segments, with manufacturing, partnerships, and regional operations across touchpoints in the United States, India, Honduras, and other markets.
Based on the available content, Crassula’s core strengths lie in “formulation + delivery technology + GMP manufacturing + commercial scale-up.” The company provides end-to-end support spanning formulation development, process validation, technology transfer, packaging, serialization, regulatory documentation, and supply. Its key technology platform, QuanticSphere™, focuses on multilayer nano/phospholipid sphere delivery, designed to protect active ingredients, regulate the location and timing of release, and improve solubility, absorption, stability, and gastrointestinal tolerability. It is especially suited to fat-soluble or complex active ingredients.
The website does not disclose standard packages, project quotes, or payment methods. Its business model is closer to project-based CDMO services, co-development, private label, licensing, and regional partnerships, rather than subscription-based software. Buyers typically need to discuss commercial terms based on dosage form, batch size, target registration markets, quality standards, and the scope of technology transfer.
Crassula emphasizes its WHO-GMP quality system, ISO 9001:2015 quality management, and ISO 14001:2015 environmental management. It also provides audit materials such as SDS, SOPs, batch records, QC logs, stability data, labeling, and packaging compliance documents. For pharmaceutical and nutritional product clients, this is an important selling point. However, the pages do not provide certificate numbers, audit reports, production capacity, or market-specific approval lists, so due diligence is still required before entering into a formal partnership.
The advantages are that it covers the full lifecycle of pharmaceuticals and nutritional products, offers differentiated delivery technology, and has integrated capabilities in formulation, manufacturing, packaging, and regulatory documentation. The drawbacks are that the publicly available information is relatively marketing-oriented and lacks pricing, capacity details, original clinical evidence, certificate specifics, and information on digital system capabilities. It also does not disclose enterprise software-related details such as APIs, permissions, or cloud deployment.
It is better suited to regional pharmaceutical companies, nutritional supplement brands, OTC companies, healthcare channel partners, and teams looking for private label, licensing, or technology transfer opportunities. The text does not specify access conditions from China, so actual testing is required. If the goal is China registration, import, or cross-border sales, local regulations, filing requirements, and supply chain compliance will need to be evaluated separately.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on crassulapharma.com official site.
crassulapharma.com is an Unknown Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach crassulapharma.com directly.